Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals Chief Business-Strategy Officer Patrick Lin bought additional company stock. On an open-market purchase, he acquired 1,582 shares of common stock at $2.57 per share. After this trade, he directly owns 9,176 shares. A separate holding entry shows 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of 1,829 shares of Common Stock at $2.57 per share. After this trade, she directly owns 9,840 shares and is also shown with 333 shares held indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng reported buying 1,843 shares of common stock in an open-market transaction at $2.97 per share. Following this purchase, he holds 7,841 shares directly.
The filing also shows indirect holdings of 800 shares through the Ng Cha Family Trust and 3,488 shares through an account labeled George Ng IRRA FOB George Ng. A footnote notes an immaterial correction to a prior Form 4, adjusting an April 30, 2026 purchase to $2.71 per share and reducing that earlier trade by 15 shares.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on May 15, 2026. After this trade, he directly holds 15,345 common shares.
The filing also reports indirect holdings of 742 shares through CorLyst, LLC, 432 shares through family entities, and 1,242 shares through the Young-Plaisance Revocable Trust as of the same date. A footnote states that share amounts were adjusted to correct immaterial errors in a prior Form 4, including a corrected April 30, 2026 purchase price of $2.71 per share instead of $2.69, which reduced that earlier purchase by 13 shares.
Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin reported an open-market purchase of 1,369 shares of common stock at $2.97 per share. Following this transaction, he directly owns 7,594 shares and indirectly holds 1,740 shares through the Lin Family Trust dated February 4, 2024.
A footnote states that share figures were adjusted to correct immaterial errors in a prior Form 4. The corrected price per share for a purchase on April 30, 2026 is $2.71 instead of $2.69, which reduced that earlier purchase by 11 shares.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of 1,583 shares of common stock at $2.97 per share. After this trade, she directly holds 8,011 shares and is also shown with 333 shares held indirectly through CorLyst, LLC.
The filing also corrects earlier data, noting that a purchase on April 30, 2026 was executed at $2.71 per share instead of $2.69, which reduces that earlier purchase by 13 shares. This adjustment is described as correcting immaterial errors in a prior Form 4.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of the company’s Common Stock. On May 15, he bought 1,984 shares at $2.97 per share, bringing his direct holdings to 8,466 shares.
The filing also notes that share totals were adjusted to correct immaterial errors in a prior Form 4. The corrected price for a purchase on April 30 is stated as $2.71 instead of $2.69, which reduced that earlier purchase by 16 shares.
Processa Pharmaceuticals Chief Executive Officer George K. Ng reported an open-market purchase of 1,843 shares of Common Stock at $2.97 per share. After this transaction, his directly held Common Stock position reported in this filing increased to 3,979 shares.
The filing also lists indirect holdings of 800 shares held by the Ng Cha Family Trust and 3,488 shares held by an account identified as George Ng IRRA FOB George Ng as of the same date.
Processa Pharmaceuticals, Inc. Chief Development Officer Sian Bigora reported an open-market purchase of 1,971 shares of common stock at $2.71 per share. Following this transaction, she directly holds 7,481 shares of common stock.
The filing also reports 267 shares of common stock held indirectly through CorLyst, LLC. A footnote states that shares were adjusted to correct immaterial errors, indicating minor corrections to previously reported share amounts.
Processa Pharmaceuticals filed an amendment to a Schedule 13G/A reporting that CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. beneficially own 200,000 shares of common stock, representing 7.0% of the class. The filing notes these shares consist of warrants and cites 2,677,835 Shares outstanding as of March 31, 2026.
The joint filing clarifies that Heights Capital Management serves as investment manager to CVI Investments and may exercise voting and dispositive power; both Reporting Persons disclaim beneficial ownership except for pecuniary interest. Signatures are dated May 13, 2026.